PE20110854A1 - DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 - Google Patents

DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1

Info

Publication number
PE20110854A1
PE20110854A1 PE2011000789A PE2011000789A PE20110854A1 PE 20110854 A1 PE20110854 A1 PE 20110854A1 PE 2011000789 A PE2011000789 A PE 2011000789A PE 2011000789 A PE2011000789 A PE 2011000789A PE 20110854 A1 PE20110854 A1 PE 20110854A1
Authority
PE
Peru
Prior art keywords
pyrazolo
pyridine
alkyl
antagonists
carbonylamine
Prior art date
Application number
PE2011000789A
Other languages
English (en)
Inventor
Brian Nicholas Cook
Salvo Darren Di
Daniel Robert Fandrick
Christian Harcken
Daniel Kuzmich
Thomas Wai-Ho Lee
Pingrong Liu
John Lord
Can Mao
Jochen Neu
Brian Christopher Raudenbush
Hossein Razavi
Jonathan Timothy Reeves
Jinhua J Song
Alan David Swinamer
Zhulin Tan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20110854A1 publication Critical patent/PE20110854A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE W, Y SON CADA UNO C, N, DONDE W, Y NO PUEDEN SER IGUALES; Ar1 Y Ar2 SON CADA UNO CARBOCICLO, HETEROARILO, HETEROCICLILO SUSTITUIDO O NO, ENTRE OTROS; R1 ES H, ALQUILO C1-C6, (ALCOXI C1-C6)-(ALQUILO C1-C6); R2 Y R3 SON CADA UNO H, ALQUILO C1-C6 Y ALQUENILO C1-C6 SUSTITUIDO O NO PARCIAL O COMPLETAMENTE POR 1-3 GRUPOS CIANO, HIDROXILO, ALCOXI C1-C6, ENTRE 0TROS. SON COMPUESTSO PREFERIDOS: 3-TRIFLUOROMETIL-BENCILAMIDA DEL ACIDO 1-(4-FLUOROFENIL)-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBOXILICO; 4-(ISOPROPILSULFAMOIL-METIL)BENCILAMIDA DEL ACIDO 1-(4-FLUOROFENIL)-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBOXILICO; ESTER METILICO DEL ACIDO 3-[5-({[1-(4-FLUOROFENIL)-1H-PIRAZOLO[3,4-c]PIRIDINA4-CARBONIL]-AMINO}-METIL)-PIRIDINA-2-SULFONIL]-PROPIONICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LA ACTIVIDAD DE CCR1, UTILES EN EL TRATAMIENTO DE INFLAMACION CRONICA, ALERGIAS, PSORIASIS, ARTRITIS REUMATOIDE, ENTRE OTROS
PE2011000789A 2008-09-26 2009-09-22 DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 PE20110854A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
PE20110854A1 true PE20110854A1 (es) 2011-12-23

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000789A PE20110854A1 (es) 2008-09-26 2009-09-22 DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1

Country Status (24)

Country Link
US (4) US7879873B2 (es)
EP (1) EP2346868B1 (es)
JP (1) JP5507567B2 (es)
KR (1) KR20110060904A (es)
CN (1) CN102227425A (es)
AP (1) AP2739A (es)
AR (1) AR073689A1 (es)
AU (1) AU2009296839A1 (es)
BR (1) BRPI0919844A2 (es)
CA (1) CA2737472A1 (es)
CL (1) CL2011000668A1 (es)
CO (1) CO6351735A2 (es)
EA (1) EA201100524A1 (es)
EC (1) ECSP11010932A (es)
IL (1) IL210857A0 (es)
MA (1) MA32655B1 (es)
MX (1) MX2011002951A (es)
NZ (1) NZ591115A (es)
PE (1) PE20110854A1 (es)
TW (1) TW201018683A (es)
UA (1) UA103634C2 (es)
UY (1) UY32140A (es)
WO (1) WO2010036632A1 (es)
ZA (1) ZA201100625B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
WO2010106333A1 (en) * 2009-03-19 2010-09-23 Medical Research Council Technology Compounds
IN2012DN03449A (es) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
JP5542214B2 (ja) * 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
BR112012013582A2 (pt) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
RU2617988C2 (ru) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2771011A4 (en) * 2011-10-24 2015-04-15 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
AU2013225531A1 (en) * 2012-03-02 2014-09-25 Forma Tm, Llc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
EA032356B1 (ru) 2014-03-17 2019-05-31 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
US9242989B2 (en) 2014-04-14 2016-01-26 Boehringer Ingelheim International Gmbh Compounds as modulators of RORγ
AU2016342310B2 (en) 2015-10-23 2020-08-27 Vifor (International) Ag Novel ferroportin inhibitors
EP3373733A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3373732A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN109069514B (zh) 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (en) * 2020-06-24 2021-12-30 Oregon Health & Science University Novel molecule for modulation of innate immune responses controlled by sting protein

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
ES2188584T3 (es) 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5616537A (en) 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
DE69413183T2 (de) 1993-06-25 1999-02-11 Kumiai Chemical Industry Co Indazolsulfonylharnstoff-derivat, verwendung und zwischenprodukte zur herstellung
EP0796258A1 (en) 1994-12-06 1997-09-24 MERCK SHARP & DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
EP0939757A1 (en) 1995-12-22 1999-09-08 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
CA2309175A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
AU5414000A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
AU5895500A (en) 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
US7294624B2 (en) * 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
AU2003224923A1 (en) 2002-04-11 2003-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic amide derivatives as cytokine inhibitors
JP4414881B2 (ja) 2002-05-31 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾール化合物およびこれを含んでなる医薬組成物
AU2003236500B9 (en) 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
EA017278B9 (ru) * 2005-06-22 2013-01-30 Кемосентрикс, Инк. Соединения азаиндазола и способы применения
BRPI0615048A2 (pt) 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2009513677A (ja) 2005-10-25 2009-04-02 スミスクライン・ビーチャム・コーポレイション 化合物
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (en) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
IN2012DN03449A (es) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
BR112012013582A2 (pt) 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists

Also Published As

Publication number Publication date
US8063065B2 (en) 2011-11-22
US20120035370A1 (en) 2012-02-09
CL2011000668A1 (es) 2011-10-28
AP2739A (en) 2013-09-30
US20100093724A1 (en) 2010-04-15
US20120136158A1 (en) 2012-05-31
EP2346868B1 (en) 2016-01-27
ZA201100625B (en) 2011-09-28
WO2010036632A1 (en) 2010-04-01
EP2346868A1 (en) 2011-07-27
US20110086846A1 (en) 2011-04-14
CO6351735A2 (es) 2011-12-20
IL210857A0 (en) 2011-04-28
ECSP11010932A (es) 2011-04-29
AR073689A1 (es) 2010-11-24
AU2009296839A1 (en) 2010-04-01
JP2012503664A (ja) 2012-02-09
MA32655B1 (fr) 2011-09-01
CN102227425A (zh) 2011-10-26
AP2011005685A0 (en) 2011-04-30
UA103634C2 (en) 2013-11-11
US7879873B2 (en) 2011-02-01
KR20110060904A (ko) 2011-06-08
CA2737472A1 (en) 2010-04-01
JP5507567B2 (ja) 2014-05-28
BRPI0919844A2 (pt) 2019-09-24
US8163918B2 (en) 2012-04-24
NZ591115A (en) 2012-10-26
EA201100524A1 (ru) 2011-10-31
UY32140A (es) 2010-04-30
TW201018683A (en) 2010-05-16
MX2011002951A (es) 2011-04-26
US8338610B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20100562A1 (es) Derivados policiclicos de indazol como inhibidores de erk
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20091523A1 (es) Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
AR059249A1 (es) Compuesto amina trisustituido
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090770A1 (es) Derivados de benzoxazolona
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb

Legal Events

Date Code Title Description
FC Refusal